List view / Grid view
Merck announced that new Phase 2 data for its two…
24 March 2014 | By Merck
Merck announced that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver...
Sustained virologic response at post-treatment follow-up week 12 (SVR 12)…
2 November 2013 | By Merck
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied...
Merck announced the presentation of the latest interim data from…
23 April 2013 | By Merck
Merck announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial...
Agreement to conduct a Phase II clinical trial evaluating combination…
22 April 2013 | By Merck
Agreement to conduct a Phase II clinical trial evaluating combination of investigational oral candidates MK-5172 and daclatasvir for chronic hepatitis C...
VICTRELIS® is indicated for the treatment of chronic hepatitis C…
8 April 2013 | By Merck
VICTRELIS® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection...
New data from Phase III studies...
1 October 2012 | By Merck
New data from Phase III studies...
New clinical trial will evaluate an investigational therapeutic regimen with…
15 December 2011 | By Merck
New clinical trial will evaluate an investigational therapeutic regimen with VICTRELIS™ (boceprevir)...
